JPS62116519A - 人胎盤抽出細胞代謝活性化物質 - Google Patents
人胎盤抽出細胞代謝活性化物質Info
- Publication number
- JPS62116519A JPS62116519A JP61049384A JP4938486A JPS62116519A JP S62116519 A JPS62116519 A JP S62116519A JP 61049384 A JP61049384 A JP 61049384A JP 4938486 A JP4938486 A JP 4938486A JP S62116519 A JPS62116519 A JP S62116519A
- Authority
- JP
- Japan
- Prior art keywords
- placenta
- water
- ammonium sulfate
- normal
- soluble protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 71
- 239000000126 substance Substances 0.000 title claims abstract description 18
- 241000700605 Viruses Species 0.000 title claims abstract description 14
- 230000019522 cellular metabolic process Effects 0.000 title claims abstract description 8
- 230000003213 activating effect Effects 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 32
- 238000000605 extraction Methods 0.000 title description 18
- 208000006454 hepatitis Diseases 0.000 title description 8
- 231100000283 hepatitis Toxicity 0.000 title description 8
- 230000000415 inactivating effect Effects 0.000 title description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 16
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000006228 supernatant Substances 0.000 claims abstract description 15
- 208000034423 Delivery Diseases 0.000 claims abstract description 14
- 239000002244 precipitate Substances 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 8
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 13
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 13
- 239000007858 starting material Substances 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000001641 gel filtration chromatography Methods 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 18
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 238000002523 gelfiltration Methods 0.000 abstract description 4
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 3
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 201000005917 gastric ulcer Diseases 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000007853 buffer solution Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 238000010438 heat treatment Methods 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 13
- 229920005654 Sephadex Polymers 0.000 description 12
- 239000012507 Sephadex™ Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 239000013076 target substance Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000002900 effect on cell Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000019780 Liver Tonic Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000876 liver tonic Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- HIVLDXAAFGCOFU-UHFFFAOYSA-N ammonium hydrosulfide Chemical class [NH4+].[SH-] HIVLDXAAFGCOFU-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- -1 strong alkalis Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2278710A JPH03141299A (ja) | 1986-03-05 | 1990-10-16 | 牛胎盤抽出細胞代謝活性化物質 |
| JP2278711A JPH03148226A (ja) | 1986-03-05 | 1990-10-16 | 動物臓器由来蛋白質のウィルス不活化法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60-159713 | 1985-07-18 | ||
| JP15971385 | 1985-07-18 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2278711A Division JPH03148226A (ja) | 1986-03-05 | 1990-10-16 | 動物臓器由来蛋白質のウィルス不活化法 |
| JP2278710A Division JPH03141299A (ja) | 1986-03-05 | 1990-10-16 | 牛胎盤抽出細胞代謝活性化物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62116519A true JPS62116519A (ja) | 1987-05-28 |
| JPH0471894B2 JPH0471894B2 (enExample) | 1992-11-16 |
Family
ID=15699658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61049384A Granted JPS62116519A (ja) | 1985-07-18 | 1986-03-05 | 人胎盤抽出細胞代謝活性化物質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62116519A (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0311007A (ja) * | 1989-06-06 | 1991-01-18 | Mikimoto Seiyaku Kk | 化粧品原料の製造方法 |
| JPH03148226A (ja) * | 1986-03-05 | 1991-06-25 | Ichimaru Pharcos Co Ltd | 動物臓器由来蛋白質のウィルス不活化法 |
| EP1133990A1 (en) * | 2000-03-17 | 2001-09-19 | Pier Mario Biava | Anti-tumor composition consisting of a fraction of gravid uterus or mammalian placenta |
| CN107698675A (zh) * | 2017-07-12 | 2018-02-16 | 武汉博百欧生物科技有限公司 | 分离并纯化钙卫蛋白的方法及试剂盒 |
| CN109575103A (zh) * | 2018-12-06 | 2019-04-05 | 刘力伟 | 一种分离提取胎盘或脐带组织中水溶性蛋白分子的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260519A (ja) * | 1984-05-21 | 1985-12-23 | ベーリングヴエルケ・アクチエンゲゼルシヤフト | 組織蛋白ｐｐ↓１↓８、その取得方法およびその用途 |
-
1986
- 1986-03-05 JP JP61049384A patent/JPS62116519A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260519A (ja) * | 1984-05-21 | 1985-12-23 | ベーリングヴエルケ・アクチエンゲゼルシヤフト | 組織蛋白ｐｐ↓１↓８、その取得方法およびその用途 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03148226A (ja) * | 1986-03-05 | 1991-06-25 | Ichimaru Pharcos Co Ltd | 動物臓器由来蛋白質のウィルス不活化法 |
| JPH0311007A (ja) * | 1989-06-06 | 1991-01-18 | Mikimoto Seiyaku Kk | 化粧品原料の製造方法 |
| EP1133990A1 (en) * | 2000-03-17 | 2001-09-19 | Pier Mario Biava | Anti-tumor composition consisting of a fraction of gravid uterus or mammalian placenta |
| CN107698675A (zh) * | 2017-07-12 | 2018-02-16 | 武汉博百欧生物科技有限公司 | 分离并纯化钙卫蛋白的方法及试剂盒 |
| CN109575103A (zh) * | 2018-12-06 | 2019-04-05 | 刘力伟 | 一种分离提取胎盘或脐带组织中水溶性蛋白分子的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0471894B2 (enExample) | 1992-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| D'Amore et al. | Angiogenic activity from bovine retina: partial purification and characterization. | |
| Evanson et al. | Human collagenase: identification and characterization of an enzyme from rheumatoid synovium in culture | |
| Evanson et al. | Studies on collagenase from rheumatoid synovium in tissue culture | |
| Wakabayashi et al. | The immunospecificity of nonhistone protein complexes with DNA | |
| ATE385810T1 (de) | Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren | |
| JPH0374647B2 (enExample) | ||
| JPS61502334A (ja) | 細胞表面蛋白質とその製法及びその使用法 | |
| JPS62116519A (ja) | 人胎盤抽出細胞代謝活性化物質 | |
| JPH06312922A (ja) | 美白剤 | |
| OzAwA et al. | Partial purification of a factor promoting chicken myoblast multiplication in vitro | |
| JPH07505893A (ja) | 免疫学的機能不全を伴う疾患の治療のための方法および組成物 | |
| JPH0571600B2 (enExample) | ||
| JPH06234798A (ja) | 牛胎盤抽出細胞代謝活性化物質 | |
| JPS63188697A (ja) | 牛脾臓由来の細胞増殖促進物質 | |
| Chen et al. | Vascular endothelial cell effectors in fetal calf retina, vitreous, and serum. | |
| US6231862B1 (en) | Purified new epididymal forward motility protein and a process for the isolation of the said epididymal forward motility protein useful as a fertility prometer/blocker | |
| JPS63188698A (ja) | 牛胸腺由来の細胞増殖促進物質 | |
| JPH05500809A (ja) | 新規タンパク質及びその製造 | |
| JPS63188699A (ja) | 牛の乳房から抽出せる細胞増殖促進物質及びその抽出法並びにウイルス不活化処理法 | |
| Bag | Free messenger ribonucleoprotein complexes of chicken primary muscle cells following modification of protein synthesis by heat‐shock treatment | |
| US6306823B1 (en) | Purified new epididymal forward motility protein and a process for isolation of the said epididymal forward motility protein useful as a fertility promoter/blocker | |
| JPS63188700A (ja) | 牛の血液又は血清から抽出せる細胞増殖促進物質及びその抽出法並びにウイルス不活化処理法 | |
| Rich et al. | [38] Isolation of soluble elastin-lathyrism | |
| MATUDA et al. | Isolation of the mitosis promoting substance, oncotrephin, from rat ascites hepatoma (AH 130) | |
| AU676464B2 (en) | Proteolytic mixture containing escharase and method of isolating same |